Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Cipher Pharmaceuticals Inc
T.CPH
Alternate Symbol(s):
CPHRF
Healthcare
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology...
products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:CPH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(7)
•••
stef1234
X
View Profile
View Bullboard History
Post by
stef1234
on Oct 03, 2023 10:00pm
Comprehensive Valuation Report on Cipheras of August 31 2023
A very interesting reading found in Issuer Bid Circular issued in September. You can find a Comprehensive valuation report on Cipher in the last 40 pages of the issuer bid circular made by Evans
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 03, 2023 7:02am
New Press Release - Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid
MISSISSAUGA, ON, Oct. 3, 2023 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company"), today provided a reminder of its previously announced substantial issuer bid (the "Offer" or "SIB") under which the Company has offered to purchase for cancellation up to $6,000,000 of its...
read article.
Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million
posted Nov 21, 2024 9:00am by
Innocan Pharma Corp
-
|
"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more
(9)
•••
drewmumaw
X
View Profile
View Bullboard History
Comment by
drewmumaw
on Sep 26, 2023 5:07pm
RE:Cipher share price is ahead of Knight Therapeutics this a.m.
My initial reaction to the Dutch auction was that it was another way—in addition to the NCIB—to shake out paper hands before they make an acquisition that may lift the share price significantly higher
...more
(5)
•••
PitchinPennies
X
View Profile
View Bullboard History
Post by
PitchinPennies
on Sep 25, 2023 12:15pm
Cipher share price is ahead of Knight Therapeutics this a.m.
Cipher passed Knight? I have to admit I didn't see this happening -- ever. Probably reflects more on what Knight failed to accomplish with its great resources, and less on Craig Mull's having
...more
(2)
•••
ValueCat
X
View Profile
View Bullboard History
Post by
ValueCat
on Sep 21, 2023 1:20pm
Big bids
Trading massively above the range. bump on the way?
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Sep 18, 2023 1:23pm
Ink Research
Morning Report: Cipher Pharmaceuticals makes its mark in the INK Top 40 September 18, 2023 Cipher Pharmaceuticals (CPH) stock has been on a steady rise over the past year,
...more
(6026)
•••
retiredcf
X
View Profile
View Bullboard History
Post by
retiredcf
on Sep 18, 2023 1:21pm
Ryan Irvine
He and his partner (Aaron Dunn) made their annual appearance at the Toronto MoneyShow on 8 Feb. For those who are unfamiliar with them, their firm (Keystone Financial) analyses over 4000
...more
(9)
•••
drewmumaw
X
View Profile
View Bullboard History
Comment by
drewmumaw
on Aug 29, 2023 4:38pm
RE:Adieu
Adieu Monsieur. I’ve appreciated your input over the years on this board. Hopefully, you come back in the future. I agree with your general overview regarding Cipher’s declining business. I continue
...more
(164)
•••
Northforce13
X
View Profile
View Bullboard History
Post by
Northforce13
on Aug 29, 2023 9:40am
Adieu
I bid you all "adieu" fellow CPH investors, it's been a fantastic fun ride :-) CPH remains a good stock at a decent price, but no longer a great bargain, so I have taken my winnings off
...more
(164)
•••
Northforce13
X
View Profile
View Bullboard History
Comment by
Northforce13
on Aug 07, 2023 11:10am
RE:RE:Cipher Partner, Moberg Pharma Announces Approval for MOB-015
The U.S. requires two phase 3 studies for approval. EU does not, if I remember correctly Moberg is taking advantage of the second phase 3 to try using a shorter treatment period, allowing more
...more
(9)
•••
drewmumaw
X
View Profile
View Bullboard History
Comment by
drewmumaw
on Jul 21, 2023 10:51am
RE:Cipher Partner, Moberg Pharma Announces Approval for MOB-015
I find it a bit odd that the nail whitening issue requires an additional phase 3 trial to gain approval in the US and Canada, but the European Union approved it regardless. The purpose of this
...more
(126)
•••
Daudau11
X
View Profile
View Bullboard History
Post by
Daudau11
on Jul 05, 2023 8:01am
Cipher Partner, Moberg Pharma Announces Approval for MOB-015
Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union T.CPH | 57 minutes ago Significant regulatory milestone
...more
(0)
•••
evenhand
X
View Profile
View Bullboard History
Comment by
evenhand
on Jul 04, 2023 1:06pm
RE:SCD Interview on YouTube
Almost the same story as in the run up of a few years back. "They are ready to grow". I have held some shares since then just to see if I can get some of my money back. A hobby
...more
(1)
•••
GJS471
X
View Profile
View Bullboard History
Comment by
GJS471
on Jul 01, 2023 11:49am
RE:RE:RE:RE:RE:CPH: Outperformer, Give Credit When Credit Is Due
The compensation numbers speak for them selves. As for the roles they play, I think they better start playing them soon. Here are the numbers for the Q1 report regarding compensation
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden